mRNA-based dendritic cell vaccines

被引：123

作者：

Benteyn, Daphne ^{[1
]}

Heirman, Carlo ^{[1
]}

Bonehill, Aude ^{[1
]}

Thielemans, Kris ^{[1
,2
]}

Breckpot, Karine ^{[1
]}

机构：

[1] Vrije Univ Brussel, Lab Mol & Cellular Therapy, Dept Biomed Sci, B-1090 Jette, Belgium

[2] Vrije Univ Brussel, Dendrit Cell Bank, B-1090 Jette, Belgium

来源：

EXPERT REVIEW OF VACCINES | 2015年 / 14卷 / 02期

关键词：

cancer; cytotoxic T cell; dendritic cell; mRNA; tumor antigen; ANTIGEN-SPECIFIC CD8(+); CONSTITUTIVELY ACTIVE TLR4; IN-VITRO DIFFERENTIATION; TUMOR-ASSOCIATED ANTIGEN; CYTOTOXIC T-LYMPHOCYTES; THERAPEUTIC VACCINATION; CANCER-PATIENTS; INTERFERON-BETA; IMMUNOSTIMULATORY FUNCTION; IMMUNOLOGICAL RESPONSE;

D O I：

10.1586/14760584.2014.957684

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Cancer immunotherapy has been proposed as a powerful treatment modality. Active immunotherapy aspires to stimulate the patient's immune system, particularly T cells. These cells can recognize and kill cancer cells and can form an immunological memory. Dendritic cells (DCs) are the professional antigen-presenting cells of our immune system. They take up and process antigens to present them to T cells. Consequently, DCs have been investigated as a means to stimulate cancer-specific T-cell responses. An efficient strategy to program DCs is the use of mRNA, a well-defined and safe molecule that can be easily generated at high purity. Importantly, vaccines consisting of mRNA-modified DCs showed promising results in clinical trials. Therefore, we will introduce cancer immunotherapy and DCs and give a detailed overview on the application of mRNA to generate cancer-fighting DC vaccines.

引用

页码：161 / 176

页数：16

共 157 条

[1] Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients [J].

Aarntzen, Erik H. J. G. ;

Schreibelt, Gerty ;

Bol, Kalijn ;

Lesterhuis, W. Joost ;

Croockewit, Alexandra J. ;

de Wilt, Johannes H. W. ;

van Rossum, Michelle M. ;

Blokx, Willeke A. M. ;

Jacobs, Joannes F. M. ;

Duiveman-de Boer, Tjitske ;

Schuurhuis, Danita H. ;

Mus, Roel ;

Thielemans, Kris ;

de Vries, I. Jolanda M. ;

Figdor, Carl G. ;

Punt, Cornelis J. A. ;

Adema, Gosse J. .

CLINICAL CANCER RESEARCH, 2012, 18 (19) :5460-5470

[2] Cotransfection of DC with TLR4 and MART-1 RNA induces MART-1-specific responses [J].

Abdel-Wahab, Z ;

Cisco, R ;

Dannull, J ;

Ueno, T ;

Abdel-Wahab, O ;

Kalady, MF ;

Onaitis, MW ;

Tyler, DS ;

Pruitt, SK .

JOURNAL OF SURGICAL RESEARCH, 2005, 124 (02) :264-273

[3] CD83 expression on dendritic cells and T cells: Correlation with effective immune responses [J].

Aerts-Toegaert, Cindy ;

Heirman, Carlo ;

Tuyaerts, Sandra ;

Corthals, Jurgen ;

Aerts, Joeri L. ;

Bonehill, Aude ;

Thielemans, Kris ;

Breckpot, Karine .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2007, 37 (03) :686-695

[4] IL-4 is more effective than IL-13 for in vitro differentiation of dendritic cells from peripheral blood mononuclear cells [J].

Ahn, JS ;

Agrawal, B .

INTERNATIONAL IMMUNOLOGY, 2005, 17 (10) :1337-1346

[5] Clinical use of dendritic cells for cancer therapy [J].

Anguille, Sebastien ;

Smits, Evelien L. ;

Lion, Eva ;

van Tendeloo, Viggo F. ;

Berneman, Zwi N. .

LANCET ONCOLOGY, 2014, 15 (07) :E257-E267

[6] Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy [J].

Anguille, Sebastien ;

Lion, Eva ;

Van den Bergh, Johan ;

Van Acker, Heleen H. ;

Willemen, Yannick ;

Smits, Evelien L. ;

Van Tendeloo, Viggo F. ;

Berneman, Zwi N. .

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (09) :1956-1961

[7] Interleukin-15-Induced CD56+ Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential [J].

Anguille, Sebastien ;

Lion, Eva ;

Tel, Jurjen ;

de Vries, I. Jolanda M. ;

Coudere, Karen ;

Fromm, Phillip D. ;

Van Tendeloo, Viggo F. ;

Smits, Evelien L. ;

Berneman, Zwi N. .

PLOS ONE, 2012, 7 (12)

[8] Selective Activation of Intracellular Signalling Pathways in Dendritic Cells for Cancer Immunotherapy [J].

Arce, Frederick ;

Kochan, Grazyna ;

Breckpot, Karine ;

Stephenson, Holly ;

Escors, David .

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2012, 12 (01) :29-39

[9] Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial [J].

Baek, Soyoung ;

Kim, Choung-Soo ;

Kim, Sung-Bae ;

Kim, Yong-man ;

Kwon, Seog-Woon ;

Kim, YongMan ;

Kim, HyunSoo ;

Lee, Hyunah .

JOURNAL OF TRANSLATIONAL MEDICINE, 2011, 9

[10] IL-13 replaces IL-4 in development of monocyte derived dendritic cells (MoDC) of swine [J].

Bautista, Elida M. ;

Nfon, Charles ;

Ferman, Geoffery S. ;

Golde, William T. .

VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2007, 115 (1-2) :56-67

← 1 2 3 4 5 6 7 8 9 10 →